Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

321.44 -3.95 (-1.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,442,485
Open 323.65
Bid (Size) 321.11 (2)
Ask (Size) 323.45 (1)
Prev. Close 325.39
Today's Range 320.50 - 324.82
52wk Range 248.38 - 346.85
Shares Outstanding N/A
Dividend Yield 2.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily

Performance

YTD
+8.09%
+8.09%
1 Month
-4.24%
-4.24%
3 Month
+2.87%
+2.87%
6 Month
+13.30%
+13.30%
1 Year
+21.83%
+21.83%

More News

Read More
Smart Money Is Betting Big In AMGN Options
Via Benzinga
MarketBeat Week in Review – 8/5 - 8/9
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Amgen's Options: A Look at What the Big Money is Thinking
Via Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal
Via Talk Markets
Topics Stocks
Exposures US Equities
Here's Why Eli Lilly Stock Dropped 12% Last Month
Via The Motley Fool
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
Via Benzinga
Why Amgen Stock Is Down Today Despite Solid Q2 Results
Via The Motley Fool
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
Via Benzinga
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
Via Benzinga
Amgen's MariTide Weight Loss Potential: Stock Outlook
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property Product Safety
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
Via Benzinga
Topics Stocks
Exposures US Equities
AMGN Stock Earnings: Amgen Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Amgen Undercuts Its Buy Point On Mixed Second-Quarter Report
Via Investor's Business Daily
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
Via Benzinga
Topics Stocks
Exposures US Equities
Good Stocks, Strategic Options, and a 4.5% Yield: There's a Lot to Like About This Unique ETF
Via The Motley Fool
Topics ETFs
So Much For Expecting The Fed To Stick The Landing
Via Talk Markets
Topics Economy
Exposures Interest Rates
3 Biotech Stocks That Could Have Investors Grinning Soon
Via InvestorPlace
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
Via The Motley Fool
The Top 3 Biotech Stocks to Buy Now Summer 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.